Literature DB >> 21533545

Identification of novel subregions of LOH in gastric cancer and analysis of the HIC1 and TOB1 tumor suppressor genes in these subregions.

Jingcui Yu1, Peng Liu, Xiaobo Cui, Yu Sui, Guohua Ji, Rongwei Guan, Donglin Sun, Wei Ji, Fangli Liu, An Liu, Yuzhen Zhao, Yang Yu, Yan Jin, Jing Bai, Jingshu Geng, Yingwei Xue, Jiping Qi, Ki-Young Lee, Songbin Fu.   

Abstract

Previously, we identified 3 overlapping regions showing loss of heterozygosity (LOH, R(1)-R(3) from 11 to 30 cM) on chromosome 17 in 45 primary gastric cancers (GCs). The data indicated the presence of tumor suppressor genes (TSGs) on chromosome 17 involved in GC. Among the putative TSGs in these regions, HIC1 (in SR(1)) and TOB1 (in SR(3)) remain to be examined in GC. By immunohistochemistry (IHC), methylation-specific PCR (MSP) and western blot, we evaluated the expression and regulation status for HIC1 and TOB1 protein in GC. We narrowed down the deletion intervals on chromosome 17 and defined five smaller LOH subregions, SR(1)-SR(5) (0.54 to 3.42 cM), in GC. We found that HIC1 had downregulated expression in 86% (91/106) and was methylated in 87% (26/30) of primary GCs. Of the primary GCs showing downregulation of HIC1 protein, 75% (18/24) had methylated HIC1 gene. TOB1 was either absent or expressed at reduced levels in 75% (73/97) of the GC samples. In addition, a general reduction was found in total and the ratio of unphosphorylated to phosphorylated TOB1 protein levels in the differentiated GC cell lines. Further analysis revealed significant simultaneous downregulation of both HIC1 and TOB1 protein in GC tissue microarray samples (67%, 52/78) and in primary GCs (65%, 11/17). These results indicate that silencing of HIC1 and TOB1 expression is a common occurrence in GC and may contribute to the development and progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533545      PMCID: PMC3855460          DOI: 10.1007/s10059-011-2316-4

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  32 in total

1.  Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer.

Authors:  S Semba; H Yokozaki; W Yasui; E Tahara
Journal:  Int J Oncol       Date:  1998-06       Impact factor: 5.650

2.  Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer.

Authors:  H Fujii; M A Biel; W Zhou; S A Weitzman; S B Baylin; E Gabrielson
Journal:  Oncogene       Date:  1998-04-23       Impact factor: 9.867

3.  Association between CpG island methylation and microsatellite instability in colorectal cancer.

Authors:  N Ahuja; A L Mohan; Q Li; J M Stolker; J G Herman; S R Hamilton; S B Baylin; J P Issa
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

Review 4.  Genetic pathways of two types of gastric cancer.

Authors:  Eiichi Tahara
Journal:  IARC Sci Publ       Date:  2004

5.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.

Authors:  M M Wales; M A Biel; W el Deiry; B D Nelkin; J P Issa; W K Cavenee; S J Kuerbitz; S B Baylin
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

6.  Rapid detection of loss of heterozygosity of chromosome 17p by polymerase chain reaction-based variable number of tandem repeat analysis and detection of single-strand conformation polymorphism of intragenic p53 polymorphisms.

Authors:  B Dockhorn-Dworniczak; C Poremba; R Dantcheva; A Stücker; E Brömmelkamp; S Blasius; W Mellin; A Roessner; D W Yandell; W Böcker
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

8.  Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer.

Authors:  K M Fong; Y Kida; P V Zimmerman; M Ikenaga; P J Smith
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

9.  DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma.

Authors:  Qinghua Feng; Georgios Deftereos; Stephen E Hawes; Joshua E Stern; Julia B Willner; Elizabeth M Swisher; Longfu Xi; Charles Drescher; Nicole Urban; Nancy Kiviat
Journal:  Gynecol Oncol       Date:  2008-08-30       Impact factor: 5.482

10.  Alteration of expression or phosphorylation status of tob, a novel tumor suppressor gene product, is an early event in lung cancer.

Authors:  Kentaro Iwanaga; Naoko Sueoka; Akemi Sato; Toru Sakuragi; Yukinori Sakao; Masaki Tominaga; Toru Suzuki; Yutaka Yoshida; Junko K-Tsuzuku; Tadashi Yamamoto; Shinichiro Hayashi; Kohei Nagasawa; Eisaburo Sueoka
Journal:  Cancer Lett       Date:  2003-12-08       Impact factor: 8.679

View more
  12 in total

Review 1.  DNA methylation and microRNAs in cancer.

Authors:  Xiang-Quan Li; Yuan-Yuan Guo; Wei De
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  The polymorphism in miR-25 attenuated the oncogenic function in gastric cancer.

Authors:  Jianping Zhou; Jiangang Zhou; Weimin Wang; Weiling Li; Lulu Wu; Gang Li; Jun Shi; Sujun Zhou
Journal:  Tumour Biol       Date:  2015-11-16

3.  Glutamine depletion and glucose depletion trigger growth inhibition via distinctive gene expression reprogramming.

Authors:  Shuo Qie; Dongming Liang; Chengqian Yin; Weiting Gu; Meng Meng; Chenguang Wang; Nianli Sang
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

4.  Phosphorylation of TOB1 at T172 and S320 is critical for gastric cancer proliferation and progression.

Authors:  Dong Wang; He Song; Tie Zhao; Mengxi Wang; Yanhong Wang; Lina Yu; Ping Wang; Jingcui Yu
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 5.  Deciphering HIC1 control pathways to reveal new avenues in cancer therapeutics.

Authors:  Brian R Rood; Dominique Leprince
Journal:  Expert Opin Ther Targets       Date:  2013-04-09       Impact factor: 6.902

6.  Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β‑catenin signaling.

Authors:  Juthika Kundu; S M Riajul Wahab; Joydeb Kumar Kundu; Yoon-La Choi; Ozgur Cem Erkin; Hun Seok Lee; Sang Gyu Park; Young Kee Shin
Journal:  Int J Oncol       Date:  2012-06-12       Impact factor: 5.650

Review 7.  Transducer of ERBB2.1 (TOB1) as a Tumor Suppressor: A Mechanistic Perspective.

Authors:  Hun Seok Lee; Juthika Kundu; Ryong Nam Kim; Young Kee Shin
Journal:  Int J Mol Sci       Date:  2015-12-15       Impact factor: 5.923

8.  Decreased TOB1 expression and increased phosphorylation of nuclear TOB1 promotes gastric cancer.

Authors:  Rongwei Guan; Lei Peng; Dong Wang; Hongjie He; Dexu Wang; Rui Zhang; Hui Wang; Huiting Hao; Jian Zhang; He Song; Shuning Sui; Xiangning Meng; Xiaobo Cui; Jing Bai; Wenjing Sun; Songbin Fu; Jingcui Yu
Journal:  Oncotarget       Date:  2017-09-08

9.  Association between the SNPs of the TOB1 gene and gastric cancer risk in the Chinese Han population of northeast China.

Authors:  Hui Wang; Huiting Hao; Haonan Guo; Yuanyuan Wang; Xuelong Zhang; Lidan Xu; Jingcui Yu
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

10.  Association between HIC1 promoter methylation and solid tumor: A meta-analysis.

Authors:  Tie Zhao; Justice Afrifa; Dong Wang; Jingcui Yu
Journal:  EXCLI J       Date:  2020-04-07       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.